NCT00364286 2026-01-20
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
6 trialsNCT01441882 2021-04-08
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00438854 2017-12-13
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
Massachusetts General Hospital
Phase 2 Completed
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT00563290 2015-06-18
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01051115 2011-08-31
D'ACCORD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown